Issue of Equity & Director Shareholding

RNS Number : 3982E

Advanced Oncotherapy PLC

08 May 2017

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Issue of Equity

& Director Shareholding

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Nick Plowman, Non-Executive Director, will invest £250,000 in the Company.

The investment will be satisfied through the issue of 833,333 new ordinary shares of 25 pence nominal value (the "New Shares") in the capital of the Company at a price of 30p per New Share. Application will be made for the New Shares to be admitted to trading on AIM ("Admission") on or around 12 May 2017.

Dr Nick Plowman is the UK's senior radiotherapist and was appointed as Non-Executive Director of the Company in February 2017, having been Chairman of the Medical Advisory Board since October 2013. Dr Plowman is Senior Clinical Oncologist at St Bartholomew's Hospital ("Barts") and the Hospital for Sick Children at Great Ormond Street ("GOSH") in London.

Following Admission, Dr Plowman will hold 3,470,132 Ordinary Shares, representing 4.58% of the enlarged issued share capital.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 75,785,194 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 75,785,194. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Advanced Oncotherapy Plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior / Ben Maddison	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

IOEEAASXEANXEAF